THERAPEUTIC STRATEGY COMBINING INTRAVENOUS CYCLOPHOSPHAMIDE FOLLOWED BY ORAL MYCOPHENOLATE MOFETIL TO TREAT SEVERE OR WORSENING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS

被引：0
|
作者：
Duchange, Al [1 ]
Mouthon, L. [2 ]
Berezne, A. [2 ]
Morell-Dubois, S. [1 ]
Hatron, P. Y. [1 ]
Guillevin, L. [2 ]
Hachulla, E. [1 ]
Launay, D. [1 ]
机构：
[1] Hop Claude Huriez, Ctr Reference Sclerodermie, CHRU, Serv Med Interne, Lille, France
[2] Hop Cochin, Ctr Reference Vasc & Sclerodermie, Serv Med Interne, F-75674 Paris, France
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2010年 / 28卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [31] Analysis of patients with interstitial lung disease associated to Systemic Sclerosis treated with cyclophosphamide
    Arreguy Nogueira, Luiz Paulo
    Mancuzo, Eliane
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [32] A RANDOMISED CONTROLLED TRIAL TO COMPARE THE EFFICACY OF ORAL MYCOPHENOLATE MOFETIL WITH PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS RELATED EARLY INTERSTITIAL LUNG DISEASE
    Naidu, G.
    Sharma, S.
    Dhir, V.
    Dhooria, S.
    Sinha, A.
    Mb, A.
    Jain, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 751 - 752
  • [33] Therapeutic strategy combining intravenous cyclophosphamide (cyc) and azathioprine to treat severe systemic sclerosis (ssc):: A prospective open-label study including 52 patients.
    Berezné, A
    Valeyre, D
    Le Guern, V
    Brauner, M
    Mahr, A
    Constans, J
    Amoura, Z
    Pagnoux, C
    Guillevin, L
    Mouthon, L
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S163 - S163
  • [34] Efficacy of Rituximab Versus Cyclophosphamide and Mycophenolate for the Treatment of Interstitial Lung Disease in Systemic Sclerosis: A Systematic Review
    Parikh, Aneri
    Francis, Aida J.
    Sreenivasan, Chithra
    Pandey, Manorama
    AlQassab, Osamah
    Kanthajan, Tatchaya
    AlEdani, Esraa M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [35] Mycophenolate Versus Cyclophosphamide for Progressive Interstitial Lung Disease Associated with Systemic Sclerosis: A 2-Year Case Control Study
    Panopoulos, Stylianos T.
    Bournia, Vassiliki-Kalliopi
    Trakada, Georgia
    Giavri, Irene
    Kostopoulos, Charalambos
    Sfikakis, Petros P.
    LUNG, 2013, 191 (05) : 483 - 489
  • [36] Mycophenolate Versus Cyclophosphamide for Progressive Interstitial Lung Disease Associated with Systemic Sclerosis: A 2-Year Case Control Study
    Stylianos T. Panopoulos
    Vassiliki-Kalliopi Bournia
    Georgia Trakada
    Irene Giavri
    Charalambos Kostopoulos
    Petros P. Sfikakis
    Lung, 2013, 191 : 483 - 489
  • [37] MYCOPHENOLATE MOFETIL VS CYCLOPHOSPHAMIDE IN SCLERODERMA ASSOCIATED INTERSTITIAL LUNG DISEASE(ILD) - SINGLE CENTER OBSERVATIONAL STUDY
    Bavaliya, M.
    Padmanabha, S.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 34 - 34
  • [38] COMPARISON OF LONG-TERM CYCLOPHOSPHAMIDE (CY) AND MYCOPHENOLATE MOFETIL (MMF) EFFICACY AND SAFETY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ovsyannikova, O.
    Desiniva, O.
    Garzanova, L.
    Ananieva, L.
    Starovoytova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1108 - 1109
  • [39] The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease
    Wollin, L.
    Trinh-Minh, T.
    Zhang, Y.
    Distler, J. H. W.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (04) : S134 - S141
  • [40] Successful treatment by mycophenolate mofetil of subacute progressive interstitial lung disease associated with systemic lupus erythematosus
    Hanata, Norio
    Shoda, Hirofumi
    Fujio, Keishi
    MODERN RHEUMATOLOGY CASE REPORTS, 2021, 5 (01) : 43 - 46
12345